Published in BMC Neurol on June 17, 2014
Functional neuroanatomy of amygdalohippocampal interconnections and their role in learning and memory. J Neurosci Res (2016) 0.81
International Veterinary Epilepsy Task Force recommendations for a veterinary epilepsy-specific MRI protocol. BMC Vet Res (2015) 0.79
Correlation between Peripheral Levels of Brain-Derived Neurotrophic Factor and Hippocampal Volume in Children and Adolescents with Bipolar Disorder. Neural Plast (2015) 0.75
The hippocampus: detailed assessment of normative two-dimensional measurements, signal intensity, and subfield conspicuity on routine 3T T2-weighted sequences. Surg Radiol Anat (2017) 0.75
Subcortical grey matter changes in juvenile myoclonic epilepsy. Neuroimage Clin (2017) 0.75
Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage (2004) 49.54
Fast robust automated brain extraction. Hum Brain Mapp (2002) 41.79
Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage (2002) 38.46
A global optimisation method for robust affine registration of brain images. Med Image Anal (2001) 27.87
Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging (2001) 25.22
A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging (1998) 23.54
Bayesian analysis of neuroimaging data in FSL. Neuroimage (2008) 9.10
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage (2011) 6.60
Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr (2001) 2.67
Network atrophy in temporal lobe epilepsy: a voxel-based morphometry study. Neurology (2008) 2.03
Epidemiology of idiopathic generalized epilepsies. Epilepsia (2005) 2.02
Bilateral limbic diffusion abnormalities in unilateral temporal lobe epilepsy. Ann Neurol (2005) 1.93
Hippocampal atrophy, epilepsy duration, and febrile seizures in patients with partial seizures. Neurology (1999) 1.86
Medial temporal lobe atrophy in patients with refractory temporal lobe epilepsy. J Neurol Neurosurg Psychiatry (2003) 1.79
Introduction to temporal lobe epilepsy. Epilepsy Res (1996) 1.76
Thalamic diffusion and volumetry in temporal lobe epilepsy with and without mesial temporal sclerosis. Epilepsy Res (2008) 1.63
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (2011) 1.51
Progression in temporal lobe epilepsy: differential atrophy in mesial temporal structures. Neurology (2005) 1.46
Volumetric measurements of subcortical nuclei in patients with temporal lobe epilepsy. Neurology (2001) 1.44
White-matter diffusion abnormalities in temporal-lobe epilepsy with and without mesial temporal sclerosis. J Neurol Neurosurg Psychiatry (2008) 1.43
Ipsilateral and contralateral MRI volumetric abnormalities in chronic unilateral temporal lobe epilepsy and their clinical correlates. Epilepsia (2005) 1.38
Regional grey matter abnormalities in juvenile myoclonic epilepsy: a voxel-based morphometry study. Neuroimage (2007) 1.38
MRI volumetry of the thalamus in temporal, extratemporal, and idiopathic generalized epilepsy. Neurology (2003) 1.36
Altered white matter integrity in temporal lobe epilepsy: association with cognitive and clinical profiles. Epilepsia (2010) 1.36
Subcortical and cerebellar atrophy in mesial temporal lobe epilepsy revealed by automatic segmentation. Epilepsy Res (2008) 1.35
Subfield atrophy pattern in temporal lobe epilepsy with and without mesial sclerosis detected by high-resolution MRI at 4 Tesla: preliminary results. Epilepsia (2009) 1.33
Extratemporal white matter abnormalities in mesial temporal lobe epilepsy demonstrated with diffusion tensor imaging. Epilepsia (2006) 1.31
Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage (2011) 1.27
MRI-based high-dimensional hippocampal mapping in mesial temporal lobe epilepsy. Brain (2004) 1.24
Amygdala damage in experimental and human temporal lobe epilepsy. Epilepsy Res (1998) 1.22
Thalamo-cortical network pathology in idiopathic generalized epilepsy: insights from MRI-based morphometric correlation analysis. Neuroimage (2009) 1.22
Structural changes in patients with primary generalized tonic and clonic seizures. Neurology (2006) 1.15
Quantitative MRI in patients with idiopathic generalized epilepsy. Evidence of widespread cerebral structural changes. Brain (1998) 1.09
Hippocampal and thalamic atrophy in mild temporal lobe epilepsy: a VBM study. Neurology (2008) 1.04
MR imaging volumetry of subcortical structures and cerebellar hemispheres in temporal lobe epilepsy. AJNR Am J Neuroradiol (2006) 0.98
Hippocampal cell density and subcortical metabolism in temporal lobe epilepsy. Epilepsia (1999) 0.98
Automated MRI analysis for identification of hippocampal atrophy in temporal lobe epilepsy. Epilepsia (2008) 0.97
MRI reveals structural abnormalities in patients with idiopathic generalized epilepsy. Neurology (2006) 0.96
Volumetric evidence of bilateral damage in unilateral mesial temporal lobe epilepsy. Epilepsia (2006) 0.89
Regional atrophy of the basal ganglia and thalamus in idiopathic generalized epilepsy. J Magn Reson Imaging (2011) 0.87
Distinct white matter abnormalities in different idiopathic generalized epilepsy syndromes. Epilepsia (2011) 0.85
Degree of hippocampal atrophy is related to side of seizure onset in temporal lobe epilepsy. AJNR Am J Neuroradiol (2006) 0.84
Subcortical nuclei volumetry in idiopathic generalized epilepsy. Epilepsia (2005) 0.84
Unilateral thalamic hypometabolism in patients with temporal lobe epilepsy. J Formos Med Assoc (2008) 0.83
Extratemporal damage in temporal lobe epilepsy: magnetization transfer adds information to volumetric MR imaging. AJNR Am J Neuroradiol (2011) 0.81
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc (2006) 2.58
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol (2004) 1.82
Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci (2005) 1.76
Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol (2006) 1.76
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Optical coherence tomography in multiple sclerosis. Lancet Neurol (2006) 1.65
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2010) 1.59
Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2014) 1.54
Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging (2003) 1.51
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (2011) 1.51
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology (2013) 1.48
Information-theoretic metrics for visualizing gene-environment interactions. Am J Hum Genet (2007) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (2012) 1.46
Cerebellar mutism in pediatric acute disseminated encephalomyelitis. Pediatr Neurol (2010) 1.45
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.44
Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. J Vasc Interv Radiol (2013) 1.43
Semantic integration to identify overlapping functional modules in protein interaction networks. BMC Bioinformatics (2007) 1.43
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler (2004) 1.38
Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology (2006) 1.33
Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol (2011) 1.29
Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci (2009) 1.28
BioStar models of clinical and genomic data for biomedical data warehouse design. Int J Bioinform Res Appl (2005) 1.28
Risk of bone loss in men with multiple sclerosis. Mult Scler (2004) 1.27
Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage (2011) 1.27
A novel functional module detection algorithm for protein-protein interaction networks. Algorithms Mol Biol (2006) 1.25
AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environmental associations with complex phenotypes. Genetics (2008) 1.24
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. Neuroimage (2004) 1.22
Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol (2003) 1.18
Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology (2010) 1.18
The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage (2005) 1.16
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol (2013) 1.16
Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler (2011) 1.14
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci (2009) 1.11
The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc (2009) 1.10
Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol (2010) 1.10
Recent developments in imaging of multiple sclerosis. Neurologist (2011) 1.09
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol (2008) 1.07
VizStruct: exploratory visualization for gene expression profiling. Bioinformatics (2004) 1.06
Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol (2007) 1.05
The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol (2008) 1.05
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids (2005) 1.04
Validity of the California Verbal Learning Test-II in multiple sclerosis. Clin Neuropsychol (2009) 1.02
Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem (2010) 1.01
Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord (2010) 1.01
Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J Magn Reson Imaging (2012) 1.00
An information theoretic approach for analyzing temporal patterns of gene expression. Bioinformatics (2003) 1.00
Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler (2007) 0.99